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Abstract
Objective: The aim of this study was to assess the surgical and histopathological hemostatic effects of 
topical Ankaferd blood stopper (ABS) on major arterial vessel injury related to elevated intra-arterial 
blood pressure in an experimental rabbit model.
Materials and Methods: The study included 14 New Zealand rabbits. ABS was used to treat femoral 
artery puncture on 1 side in each animal and the other untreated side served as the control. Likewise, 
for abdominal aortic puncture, only 50% of the aortic injuries received topical liquid ABS and the oth-
ers did not (control). The experiment was performed under conditions of normal arterial blood pres-
sure and was repeated with a 50% increase in blood pressure. Histopathological analysis was per-
formed in all of the studied animals.
Results: Mean bleeding time in the control femoral arteries was 105.0±18.3 s, versus 51.4±9.8 s 
(p<0.05) in those treated with ABS. Mean blood loss from the punctured control femoral arteries was 
5.0±1.5 mg and 1.6±0.4 mg from those treated with ABS (p<0.05). Histopathological examination 
of the damaged arterial structures showed that ABS induced red blood cell aggregates.
Conclusion: ABS administered to experimental major arterial vessel injury reduced both bleeding time 
and blood loss under conditions of normal and elevated intra-arterial blood pressure. ABS-induced 
erythroid aggregation was prominent at the vascular tissue level. These findings will inform the design 
of future experimental and clinical studies on the anti-bleeding and vascular repairing effects of the 
novel hemostatic agent ABS. (Turk J Hematol 2011; 28: 206-12)
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Ankaferd blood stopper (ABS) is an herbal extract 
[1] that has been historically used as a hemostatic 
agent in traditional Turkish medicine [2] for centu-
ries. The herbal medicine is comprised of a standard-
ized mixture of Thymus vulgaris, Glycyrrhiza glabra, 
Vitis vinifera, Alpinia officinarum, and Urtica dioica 
[3]. Each of these herbs affect endothelium, blood 
cells,  angiogenesis,  cell  proliferation,  vascular 
dynamics, and cellular mediators. G. glabra inhibits 
angiogenesis,  and  decreases  vascular  endothelial 
growth factor production and cytokine-induced neo-
vascularization. T. vulgaris has been shown to exhib-
it  varying  levels  of  antioxidant  activity,  which  may 
help prevent in vivo oxidative damage, such as lipid 
peroxidation associated with atherosclerosis. V. vinif-
era has an anti-atherosclerotic effect. A. officinarum 
inhibits nitric oxide production in lipopolysaccharide-
activated mouse peritoneal macrophages. U. dioica 
produces hypotensive responses via a vasorelaxation 
effect mediated by the release of endothelial nitric 
oxide and the opening of potassium channels, and 
via negative inotropic action [3]. The basic mecha-
nism of action of ABS is the formation of an encapsu-
lated protein network representing focal points for 
vital erythrocyte aggregation [1]. 
ABS  was  shown  to  effectively  manage  external 
bleeding in numerous clinical settings [4-13]. ABS-
induced formation of the protein network with vital 
erythroid aggregation encompasses the entire physi-
ological  hemostatic  process.  The  ABS-induced 
hemostatic network includes important distinct com-
ponents. Vital erythroid aggregation occurs in spec-
trin and ankyrin receptors on the surface of red blood 
cells. These proteins and the required ATP bioenergy 
are  included  in  the  ABS  protein  library.  ABS  also 
upregulates  the  GATA/FOG  transcription  system, 
which affects erythroid functions. Urotensin II is also 
an essential component of ABS and represents the 
link between injured vascular endothelium, adhesive 
proteins, and active erythroid cells [14-16]. 
The aim of the present study was to assess the 
surgical and histopathological hemostatic effects of 
topical ABS on major arterial vessel injury related to 
elevated intra-arterial blood pressure in an experi-
mental rabbit model. As there are some anecdotal 
reports  on  the  use  of  ABS  in  in  different  surgical 
interventions  [17-21],  elucidation  of  the  surgical 
and  histopathological  effects  of  ABS  will  inform 
future research on this novel hemostatic agent.
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Özet
Amaç: Bu çalışmanın amacı büyük arter yaralanmalarında arter içi basınç artışı ile paralel olarak uygu-
lanan topikal Ankaferd Blood Stopper (ABS)’ın cerrahi ve histopatolojik hemostatik etkilerini deney-
sel bir tavşan modelinde değerlendirmektir.
Yöntemler ve Gereçler: Çalışma grubunu ondört Yeni Zelanda tavşanı oluşturmuştur. Hayvanların bir 
ekstremitesinde oluşturulan femoral arter hasarında ABS uygulanırken karşı ekstremite kontrol ola-
rak kullanılmıştır. Benzer biçimde, abdominal aort hasarı oluşturulan hayvanlarda, hayvanların yarı-
sında topikal ABS uygulanırken diğer grup kontrol olarak çalışmaya alınmıştır. Büyük arter kanama-
ları normal arteriyel basınç altında oluşturulmuşken, çalışma intra-arteriyel basınç %50 arttırılarak 
tekrar edilmiştir. Histopatholojik incelemeler çalışılan tüm hayvanlarda gerçekleştirilmiştir. 
Bulgular: Hasar görmüş femoral arterden gelişen ortalama ‘kanama zamanı’ ABS olmadan 105.0±18.3 
sn. iken topikal ABS uygulamasıyla 51.4±9.8 saniyeye düşürülmüştür (p<0.05). Hasar görmüş femo-
ral arterden gelişen ortalama ‘kanama miktarı’ ABS olmadan 5.0±1.5 mg iken topikal ABS uygulama-
sıyla 1.6±0.4 mg’a gerilemiştir (p<0.05). Abdominal aorta kanama modelinde ise ortalama ‘kanama 
zamanı’ ve ortalama ‘kanama miktarı’ kan basıncı yükseltildiğinde bile ABS kullanımıyla azalmasına 
karşın kontrol grupları ile farklılık istatistiksel anlamlılık düzeylerine erişmemiştir. Hasar görmüş 
arteriyel yapıların histopatolojik incelemelerinde ABS uygulaması ile ilişkili kırmızı küre aggregatları 
belirgin biçimde gözlenmiştir.
Sonuç: Topikal Ankaferd Hemostat uygulaması deneysel büyük arter modelinde “kanama zamanı” ve 
“kanama miktarı” değerlerini normal ve yüksek arter-içi basınç durumlarında aşağıya çekmiştir. ABS-
bağımlı eritroid aggregasyon vasküler doku düzeyinde belirgin olarak gösterilmiştir. Gözlemler bu yeni 
hemostatik ajan’ın kanamayı engelleyici ve damar onarımına zemin hazırlayan etkilerinin gelecek 
deneysel ve klinik çalışmalarla ortaya konulması için temel teşkil etmektedir. 
(Turk J Hematol 2011; 28: 206-12)
Anahtar kelimeler: Ankaferd, kanama, kardiyovasküler cerrahi, hemostaz
Geliş tarihi: 27 Ağustos 2010     Kabul tarihi: 05 Mart 2011 Materials and Methods
Study population
The study included 14 male white New Zealand 
rabbits  obtained  from  the  Refik  Saydam  Institute. 
The animals were kept in a room at a constant opti-
mal temperature (20-22°C) under 12 h of darkness 
and 12 h of sun light. All of the animal experiments 
were carried out in accordance with the European 
Community Council Directive of 24 November 1986 
and were approved by the Gazi University Animal 
Experiments Ethics Committee (G.Ü.ET-09.045).
Study design and experiments
The  animals  underwent  surgery  to  generate 
major arterial bleeding under normal blood pres-
sure  conditions  (set-up  1)  and  a  50%  increase  in 
arterial blood pressure (set-up 2) induced via con-
current  dopamine  infusion  (5-10  μg·kg/min)  [22]. 
Set-up 1 included 8 rabbits and set-up 2 included 6 
rabbits.  Liquid  ABS  was  topically  applied  to  the 
femoral artery puncture in 1 extremity in each ani-
mal (femoral artery 1), but not to the other extrem-
ity, which served as the control (femoral artery 2). 
Abdominal aortic injury was treated likewise; 50% 
of the aortic injuries were treated with 1 mL of liq-
uid ABS (abdominal aorta 1) and the others were 
untreated  and  served  as  the  control  (abdominal 
aorta 2). Histopathological analysis was performed 
in all the animals. 
All of the rabbits underwent surgery under prop-
er general anesthesia without intubation. An arterial 
line was placed for monitorization via the ear artery 
and infusion vein. A 22G cannula was used for cath-
eterization. Anesthesia was provided via intramus-
cular injection of ketamine hydrochloride 50 mg/kg 
and xylazine hydrochloride 5 mg/kg. All of the rab-
bits underwent femoral artery and abdominal aorta 
surgery.  After  administration  of  anesthesia,  both 
femoral arteries were explored using a sterile surgi-
cal technique, and separated from the femoral vein 
and  femoral  nerve.  The  femoral  arteries  were 
rounded with tapes and a 21G injector needle was 
inserted  once  at  90°  into  the  arteries  to  induce 
major  bleeding  [23].  After  bleeding  began  we 
immediately applied compression with gasses and 
calculated  the  bleeding  time  and  blood  loss  by 
measuring the weight of the gasses before and after 
decompression.  After  the  first  bleeding  stopped, 
major bleeding was induced in the other extremity 
using the same needle. After the second bleeding 
started we immediately applied 1 mL of liquid ABS 
and compression, and again measured the bleeding 
time and blood loss, as described above. After the 
bleeding  from  both  femoral  arteries  stopped,  we 
made a paramedian incision to explore the abdom-
inal aorta and rounded it with tapes just below the 
renal  arteries.  Major  bleeding  was  induced  using 
the  same  method  as  described  above.  After  the 
experiment we obtained vessel samples (from 0.5 
cm below and above the needle hole, just below 
the renal arteries for the abdominal aorta and femo-
ral arteries) for pathological examination. When the 
experiment was completed the rabbits were sacri-
ficed for histopathological analyses via IM pentamine 
injection. Systolic and diastolic oscillations in arte-
rial  blood  pressure  were  monitored  from  the  left 
carotid  artery  using  a  BIOPAC  MP30  recorder 
(BIOPAC System, Inc., California, USA). 
We  analyzed  the  hemoglobin,  hematocrit,  and 
INR measurements before and after the procedure, 
and  calculated  blood  loss  and  bleeding  time  as 
well.  Pathological  specimens  were  preserved  in 
formaldehyde. Histopathological assessment of the 
tissue samples was performed using standard histo-
logical  techniques,  including  formalin  fixation, 
dehydration, embedding in paraffin blocks, obtain-
ing serial transverse sections (4 μm), and hematox-
ylin-eosin  staining.  All  histopathological  investiga-
tions were carried out by the same pathologist using 
a light microscope.
Statistical analysis
All  values  are  presented  as  mean±SEM. 
Comparison of findings between the treatment and 
control femoral arteries and abdominal aortas were 
statistically  analyzed  using  the  Mann-Whitney  U 
test. Alterations in the parameters over time were 
analyzed using the Wilcoxon test. A p value <0.05 
was considered statistically significant.
Results
Mean  hemoglobin  value  before  the  procedure 
was 12.2±0.7 g/dL, versus 11.8±0.6 g/dL after the 
procedure (p>0.05). Mean INR was 1.0±0.3 before 
the  procedure  and  0.8±0.1  after  the  procedure 
(p>0.05). According to these measurements, ABS 
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parameters we studied. 
In the set-up 1 animals (normal blood pressure) 
mean bleeding time from femoral artery 2 (control) 
was 105.0±18.3 s, versus 51.4±9.8 s from femoral 
artery 1 (ABS treatment) (p<0.05) (Figure 1). Mean 
blood loss from femoral artery 2 was 5.0±1.5 mg 
and  1.6±0.4  mg  from  femoral  artery  1  (p<0.05) 
(Figure  2).  Mean  bleeding  time  from  abdominal 
aorta 1 (control) was 243.8±48.5 s, versus 205.0±94.6 
s in abdominal aorta 1 (ABS treatment) (p>0.05) 
(Figure 1). Mean blood loss was 6.6±2.6 mg from 
abdominal aorta 2 and 3.7±0.1 mg from abdominal 
aorta 1 (p>0.05) (Figure 2).
In the set-up 2 animals (elevated blood pressure) 
we intended to increase the blood pressure by 50% 
using dopamine infusion, and then performed the 
same procedure as in set-up 1 animals. We obtained 
an arterial line from the ear artery, and measured 
blood pressure before and after dopamine infusion. 
Mean  blood  pressure  before  the  procedure  was 
83.3±6.5  mmHg,  versus  137.5±11.6  mmHg  after 
starting dopamine infusion (p<0.05). Mean bleed-
ing time from femoral artery 2 was 150.8±21.6 s, 
versus 139±23.5 s from femoral artery 1 (p>0.05) 
(Figure 3). Mean blood loss was 7.1±2.9 mg from 
femoral  artery  2  and  3.1±0.7  mg  from  femoral 
artery 1 (p>0.05) (Figure 4). Mean bleeding time 
from  abdominal  aorta  2  was  306.7±208  s,  versus 
206.7±17.6  s  from  abdominal  aorta  1  (p>0.05) 
(Figure 3). Mean blood loss was 3.4±1.5 mg and 
1.8±1.2 mg from abdominal aorta 2 and 1, respec-
tively (p>0.05) (Figure 4). 
Histopathological examination of the injured ves-
sels showed that the vessel lumens were enriched 
with erythrocyte aggregates following ABS adminis-
tration (Figure 5). In contrast, control vessels had 
fewer erythrocytes, without aggregation (Figure 6).
Discussion
The  present  study  aimed  to  determine  if  ABS 
could be successfully used to control major arterial 
bleeding  from  the  femoral  artery  and  abdominal 
aorta, particularly in the presence of elevated sys-
temic  arterial  blood  pressure.  In  cardiovascular 
surgery major bleeding is an important complica-
tion that leads to morbidity and mortality. Bleeding 
sometimes cannot be controlled with current con-
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Figure 2. Femoral artery and abdominal aorta blood loss without 
dopamine infusion (normal blood pressure) (*p<0.05). 
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Figure 1. Femoral artery and abdominal aorta bleeding time with-
out dopamine infusion (normal blood pressure) (*p<0.05)
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Figure 3. Femoral artery and abdominal aorta bleeding time with 
dopamine infusion (elevated blood pressure)
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Figure 4. Femoral artery and abdominal aorta blood loss with dopa-
mine infusion (elevated blood pressure)
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when the focal surgical bleeding point cannot be 
found and/or bleeding is massive, originating from 
all of the surrounding tissues. The findings of the 
present  study  represent  a  starting  point  in  the 
search for the clinical anti-hemorrhagic effects of 
the novel liquid hemostatic agent, ABS.
In  the  present  study  bleeding  time  from  the 
injured major arteries was shorter and blood loss 
was lower following the use of ABS. Better essential 
hemostatic  parameters  were  observed  following 
administration of ABS, even in the presence of ele-
vated arterial blood pressure. Three ABS phase III 
studies [4,10,12] on vascular port insertion bleed-
ing, anterior epistaxis, and post-tonsillectomy hem-
orrhage  have  led  to  its  approval  as  a  hemostatic 
agent in Turkey. Use of ABS to control bleeding in 
gastrointestinal disorders [8, 24-27] and mediastinal 
bleeding [5,17] shed further light on its hemostatic 
efficacy. As such, the anti-hemorrhagic efficacy and 
safety of ABS was determined based on a wide vari-
ety of findings designed in different ways of clinical 
and experimental studies
ABS has the diverse dynamic reversible actions 
of  an  EPCR  and  PAI-1  inside  vascular  endothelial 
cells  in  an  HUVEC  model.  Immediate  enhanced 
expression of pro-hemostatic PAI-1 and down-regu-
lation of anti-coagulant EPCR upon exposure to ABS 
are compatible with the sudden anti-hemorrhagic 
efficacy  previously  shown  in  experimental  and 
clinical settings. The topical hemostatic efficacy of 
ABS has been previously tested in animals with nor-
mal and defective hemostasis [28,29]. Experimental 
studies have set the preclinical stage for the devel-
opment of this hemostatic product. The short-term 
hematological and biochemical safety of oral sys-
temic administration of ABS to rabbits have been 
reported.  Acute  mucosal  toxicity,  hematotoxicity, 
hepatotoxicity, nephrotoxicity, and biochemical tox-
icity were not observed during the short-term fol-
low-up of the animals [30]. Those preclinical results 
represent a starting point in the search for any pos-
sible  systemic  confounding  effects  of  ABS  when 
topically applied to internal surfaces. Use of ABS as 
a hemostatic agent for external hemorrhages and 
dental  treatment  in  humans  constitutes  the  first 
reports of ABS’s safety and efficacy in humans. A 
phase I, double-blind randomized cross-over place-
bo-controlled  clinical  study  with  a  5-d  wash-out 
period between the cross-over periods, which was 
conducted  with  healthy  volunteers,  reported  that 
ABS was safe [6]. Physiological cell-based coagula-
tion  could  be  clinically  managed  via  topical  ABS 
application, so as to prevent and treat bleeding asso-
ciated with many distinct clinicopathological states.
ABS also has pleiotropic cellular action [31], act-
ing on anti-infective [32-34], wound healing [35-37], 
vascular  dynamics  [38],  and  apoptotic  processes 
[15,39,40].  Histopathological  examination  of  the 
damaged  arterial  structures  in  the  present  study 
showed that ABS induced red blood cell aggregates, 
supporting the hypothesis that ABS-induced forma-
tion  of  the  protein  network  with  vital  erythroid 
aggregation encompasses the entire physiological 
hemostatic process.
In conclusion, topical application of ABS in an 
experimental  major  arterial  vessel  injury  model 
reduced bleeding time and blood loss under nor-
mal and elevated intra-arterial blood pressure con-
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Figure 5. ABS-induced erythrocyte aggregates in the vessel lumen 
(H&E, 100×)
Figure 6. Fewer erythrocytes next to the wall in a vessel lumen not 
administered ABS (H&E, 100×)ditions.  ABS-induced  erythroid  aggregation  was 
prominent at the vascular tissue level. The present 
study’s  findings  will  inform  the  design  of  future 
experimental and clinical studies on the anti-bleed-
ing  and  vascular  repairing  effects  of  this  novel 
hemostatic agent.
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